Compare YHC & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | VRAX |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.3M |
| IPO Year | 2023 | 2021 |
| Metric | YHC | VRAX |
|---|---|---|
| Price | $1.80 | $3.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | ★ 164.2K | 52.5K |
| Earning Date | 04-15-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,120,622.00 | N/A |
| Revenue This Year | $1,267.57 | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.42 | N/A |
| 52 Week Low | $0.02 | $0.10 |
| 52 Week High | $2.72 | $13.19 |
| Indicator | YHC | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.72 | 55.52 |
| Support Level | $0.71 | $0.22 |
| Resistance Level | $2.20 | $4.75 |
| Average True Range (ATR) | 0.20 | 0.28 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 44.26 | 33.12 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.